Drug Profile
Research programme: peptide therapeutics - Arrowhead Pharmaceuticals/Pepscan Therapeutics
Alternative Names: Optimised Homing Peptides for cancer - Arrowhead Pharmaceuticals/Pepscan; Peptide therapeutics for cancer - Arrowhead Pharmaceuticals/Pepscan; Peptide-drug conjugate (PDC) products - Arrowhead Pharmaceuticals/PepscanLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mercator Therapeutics; Pepscan Therapeutics
- Developer Alvos Therapeutics; Pepscan Therapeutics
- Class Drug conjugates; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Netherlands
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 11 Apr 2012 Arrowhead Research Corporation acquires Alvos Therapeutics